Gilead Company's subsidiary, Kite, has obtained FDA approval for a manufacturing process change that is set to reduce the manufacturing time for Yescarta® (axicabtagene ciloleucel). This milestone is expected to decrease the median turnaround time (TAT) from 16 days to 14 days.

In the realm of CAR T-cell therapies, where personalized treatment is created from a patient's white blood cells, the approval marks a significant advancement. The manufacturing process involves modifying the patient's T cells with a Chimeric Antigen Receptor (CAR) before carefully checking, preserving, and delivering the final product back to the hospital for infusion.

“For patients with relapsed or refractory large B-cell lymphoma, every day matters as the patient’s disease can be aggressive and worsen rapidly,” said Cindy Perettie, Executive Vice President, Kite. “Yescarta is the first and only treatment to demonstrate superior overall survival over the standard of care as a second-line treatment with curative intent for these patients, and today’s decision by the FDA allows us to further shorten our delivery time of Yescarta so that patients have the best possible chance of survival.”

The FDA's decision aligns with industry experts' consensus that shortening the time to Yescarta product release and delivery can significantly benefit healthcare providers at Kite Authorized Treatment Centers, allowing better support for patients.

Dr. David Miklos, a Kite clinical investigator and Chief of Blood and Marrow Transplant and Cell Therapy at Stanford University, emphasized the critical role of time in cell therapy, stating that it can be the deciding factor between a patient receiving CAR T-cell therapy or their cancer progressing beyond treatment eligibility.

Kite, with over 135 authorized treatment centers in the US and more than 400 worldwide, has treated over 17,700 patients with its CAR T-cell therapies. The company's unique approach to scaling cell therapy technology, combining capacity, speed, and reliability, has made it a global leader in the field.

Chris McDonald, SVP, Global Head of Technical Operations at Kite, highlighted the significance of manufacturing in delivering their therapies. With a reduced manufacturing time in the US, Kite aims to expand the reach of Yescarta to an even larger patient population while maintaining its 96 percent manufacturing success rate.

As the demand for CAR T-cell therapies continues to grow, Kite's ongoing efforts to increase manufacturing network capacity demonstrate its commitment to meeting the needs of physicians and their patients.